cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
Darmadi Hariyanto
Contact Email
Darmadi Hariyanto
Phone
-
Journal Mail Official
jurnalpori@gmail.com
Editorial Address
-
Location
Kota adm. jakarta pusat,
Dki jakarta
INDONESIA
Radioterapi & Onkologi Indonesia
Published by Perhimpunan Dokter Spesialis Onkologi Radiasi Indonesia
ISSN : 20869223     EISSN : -     DOI : -
Core Subject : Health, Science, Education,
Education Health Professions Medicine & Pharmacology Physics Other
Majalah Radioterapi & Onkologi Radiasi Indonesia (Journal of the Indonesian Radiation Oncology Society) dengan ISSN 2086-9223, satu-satunya majalah dalam bidang Onkologi Radiasi di Indonesia, merupakan majalah di bawah penerbit Perhimpunan Dokter Spesialis Onkologi Radiasi Indonesia (PORI). Majalah ini rutin diterbitkan sejak tahun 2010 dengan frekuensi terbitan 2 kali dalam setahun.
Arjuna Subject : -
Articles 5 Documents
 1 
Search results for , issue "Vol 13, No 1 (2022): Volume 13 No.1 January 2022" : 5 Documents clear
Annual Scientific Meeting of Indonesian Radiation Oncology Society 2021 Agustinus Darmadi Hariyanto
Radioterapi & Onkologi Indonesia Vol 13, No 1 (2022): Volume 13 No.1 January 2022
Publisher : Perhimpunan Dokter Spesialis Onkologi Radiasi Indonesia (PORI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.32532/jori.v13i1.156

Abstract

Combination of Adoptive Cell Therapy and Radiotherapy in Cancer Management Vito Filbert Jayalie; Endang Nuryadi
Radioterapi & Onkologi Indonesia Vol 13, No 1 (2022): Volume 13 No.1 January 2022
Publisher : Perhimpunan Dokter Spesialis Onkologi Radiasi Indonesia (PORI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.32532/jori.v13i1.137

Abstract

Cancer remains a healthcare burden in the world, with the increasing cases and deaths. Adoptive cell therapy (ACT) is one of the immunotherapies which modifies immune system to recognize cancer cells, which is then transfused to induce antitumoral responses in the human body. ACT works by using cancer-specific immune cells, especially Natural Killer and T cells in the form of tumor-infiltrating lymphocytes, T-cell receptor or chimeric antigen receptor. As the combination therapy with radiotherapy, radiation is able to induce tumor-associated antigen (TAA) and major histocompatibility complex (MHC) class I expression, which leads to increased immune cells around the tumor. As the result, transferred ACT to the body may be able to proliferate and perform its function well. Moreover, radiotherapy is able to downregulate regulatory T cells and myeloid-derived suppressor cells which can inhibit the role of the immune system in attacking cancer. Clinically, studies combining radiation and ACT in cancer care are limited to several types of cancer, such as metastatic melanoma, nasopharyngeal cancer, lymphoma and non-small cell lung cancer. Radiotherapy is able to increase therapeutic efficacy, especially as a bridging therapy before ACT. Nevertheless, further trials to know the potency of combining ACT and radiotherapy in other types of cancer, especially in earlier stages are needed.
Irradiation on Extramedullary Plasmacytoma of Vulva : A case report Tirawan Sutedja; Nana Supriana; Angela Giselvania; Henry Kodrat
Radioterapi & Onkologi Indonesia Vol 13, No 1 (2022): Volume 13 No.1 January 2022
Publisher : Perhimpunan Dokter Spesialis Onkologi Radiasi Indonesia (PORI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.32532/jori.v13i1.131

Abstract

Plasma cell neoplasm is a clonal plasma cell malignancy which is the result of B cell differentiation with special characteristics the presence of immunoglobulin secretion. The clinical presentation varies from monoclonal gammopathy to plasma cell leukemia. Only five to six percent of plasma cell neoplasms manifest as plasmacytoma.Solitary extramedullary plasmacytoma (EMP) in the vulva region is a rare case. The current study presents a recurrence case of EMP in left labia minora-vulva in 61-years-old patients who have undergone surgery with a complete response. Radiotherapy was given with a total dose of External Beam Radiotherapy (EBRT) 50.4 Gy and continued with brachytherapy cylinder intravagina five Gy in three fractions. Six months after complete radiation, there was no recurrence, metastasis or progression at follow-up.  
Role of Radiotherapy in Gestational Trophoblastic Neoplasia: A Case Report Arie Munandar; Viona Viona
Radioterapi & Onkologi Indonesia Vol 13, No 1 (2022): Volume 13 No.1 January 2022
Publisher : Perhimpunan Dokter Spesialis Onkologi Radiasi Indonesia (PORI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.32532/jori.v13i1.143

Abstract

Gestational trophoblastic neoplasia (GTN) is a placental tissues malignancy that is prone to massive bleeding. Multimodality treatment is often needed to treat GTN, such as surgery and radiotherapy. Radiotherapy has a palliative role in case of hemorrhage and/or intracranial metastases.Radiotherapy is effective in controlling bleeding by destructing malignant blood vessels by inducing endothelial damage and increasing signal transduction pathway leading to apoptosis and increasing adhesion of thrombocytes to vascular endothelia resulting fibrosis. No dose and fractionation schemes are proven more effective than others, but longer fractions scheme (>5 fractions) and BED10 > 39 Gy show no additional benefit in hemostatic control or in reduction of re-bleeding rate.Brain metastatic lesions are prone to bleeding that might need craniotomy for blood evacuation or brain decompression. WBRT can be given concurrently with chemotherapy in brain metastatic GTN cases. Higher WBRT total dose (>22 Gy) associated with higher 5-year local control rates.
Patients Outcome with Brain Oligometastases Treated with the SIB-IMRT Technique: Dr. Kariadi General Hospital Experience Christina Hari Nawangsih; Harman Juniardi; Dion Firli; Sigit Wirawan; Sri Rahayu Subandini; Diaza Okadimar Ariyanto
Radioterapi & Onkologi Indonesia Vol 13, No 1 (2022): Volume 13 No.1 January 2022
Publisher : Perhimpunan Dokter Spesialis Onkologi Radiasi Indonesia (PORI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.32532/jori.v13i1.142

Abstract

Brain metastases are often considered as the end of life in oncologic diseases. Previously, a standalone Whole Brain Radiotherapy (WBRT) had been the standard of care in the case of single or multiple lesions. Currently, Simultaneous Integrated Boost - Intensity Modulated Radiotherapy (SIB-IMRT) permits the delivery of simultaneous doses within a single therapy to the whole brain and the local lesion, therefore shifting the care expectation from palliative towards curative. This study summarizes the outcome in cancer patients with brain oligometastases that were treated with the SIB-IMRT technique. Between April 2020 and April 2021, a total of 29 brain oligometastases patients were treated with the SIB-IMRT technique at Dr. Kariadi General Hospital. Twenty patients completed treatment with a whole-brain dose of 37.5 Gy and tumor dose of 45 Gy, both in 15 fractions. Among fifteen who were successfully followed-up, six at the 6th-month follow-up, complete data of four patients were included. All four patients improved clinically. Evaluation from imaging revealed mass reductions in two patients, while one patient’s metastases were progressing, and the other one showed no changes. Additionally, no patients demonstrated cerebral necrosis as a late side effect.

Page 1 of 1 | Total Record : 5

 1 

Filter by Year

2022 2022


Reset
Filter By Issues
All Issue Vol 13, No 1 (2022): Volume 13 No.1 January 2022 Vol 12, No 2 (2021): VOLUME 12 NO.2 JULY 2021 Vol 12, No 1 (2021): VOLUME 12 NO.1 JANUARY 2021 Vol 11, No 2 (2020): VOLUME 11 NO.2 JULY 2020 Vol 11, No 1 (2020): VOLUME 11 NO.1 JANUARI 2020 Vol 10, No 2 (2019): VOLUME 10 NO.2 JULI 2019 Vol 10, No 1 (2019): VOLUME 10 NO.1 JANUARI 2019 Vol 9, No 2 (2018): VOLUME 9 NO. 2 JULI 2018 Vol 9, No 2 (2018): Volume 9 No.2 Juli 2018 Vol 9, No 1 (2018): Volume 9 No.1 Januari 2018 Vol 8, No 2 (2017): Volume 8 No.2 Juli 2017 Vol 8, No 1 (2017): Volume 8 No.1 Januari 2017 Vol 7, No 2 (2016): Volume 7 No.2 Juli 2016 Vol 7, No 1 (2016): Volume 7 No.1 Januari 2016 Vol 6, No 2 (2015): Volume 6 No.2 Juli 2015 Vol 6, No 1 (2015): Volume 6 No.1 Januari 2015 Vol 5, No 2 (2014): Volume 5 No.2 Juli 2014 Vol 5, No 1 (2014): Volume 5 No.1 Januari 2014 Vol 4, No 2 (2013): Volume 4 No. 2 Juli 2013 Vol 4, No 1 (2013): Volume 4 No. 1 Januari 2013 More Issue